With over 20 years’ experience in infectious disease, oncology, rare and orphan diseases and academia, Dr. McConnell will be responsible for leading the medical affairs function at Venatorx and will oversee the planning and execution of medical strategy, field medical engagement and scientific communications.
Venatorx Pharmaceuticals entered into a Research Collaboration and License Agreement with Roche to discover, characterize and develop new small molecule inhibitors of the Penicillin Binding Proteins (“PBPs”) in Gram-negative bacteria focused on agents active against carbapenem-resistant Enterobacterales (CRE).
Venatorx Pharmaceuticals, along with its collaborators, will present seven posters and two oral abstracts at IDWeek 2021, which is taking place virtually September 29 – October 3, 2021.
Venatorx Pharmaceuticals announced a comprehensive update about cefepime-taniborbactam, the Company’s intravenous beta-lactam / beta-lactamase inhibitor combination antibiotic that is being developed for the treatment of cUTIs and HABP/VABP.
VNRX-7145, in combination with ceftibuten, is designed for the treatment of patients with infections caused by multi-drug resistant (MDR) gram-negative pathogens that are resistant to current standard-of-care oral and intravenous antibiotics, including fluoroquinolones, cephalosporins and carbapenems.
For the fourth year in a row, Venatorx Pharmaceuticals was named one of the “2021 Best Places to Work” in the Greater Philadelphia area by the Philadelphia Business Journal, acknowledging our team’s unwavering commitment to bring lifesaving antibiotics and antiviral medicines to patients around the globe.
With three clinical-stage programs and a robust discovery pipeline, it is vital for us to continue to attract the best and brightest talent to Venatorx. Dr. Dorr has devoted her career to drug development. We are thrilled to have her join our team given her extraordinary track record.
The Phase 1 clinical trial will evaluate the safety and pharmacokinetics of single and multiple ascending doses of VNRX-9945, administered orally in healthy adult volunteers (ClinicalTrials.gov – NCT04845321).